Lupin receives approval from USFDA for Cyanocobalamin Nasal Spray

The United States Food and Drug Administration (U.S. FDA) has approved Cyanocobalamin Nasal Spray, 500 mcg/spray, a generic version of Nascobal® Nasal Spray, according to pharma giant Lupin Limited, which made the announcement on Monday. 

In the US, Lupin's Somerset facility will produce this item. In the United States, Cyanocobalamin Nasal Spray has anticipated yearly sales of USD 69 million. An international pharmaceutical firm with a focus on innovation, Lupin is based in Mumbai, India. 

The company creates and promotes a wide variety of branded and generic formulations, biotechnology goods, and APIs in more than 100 markets throughout the Americas, Asia Pacific, Latin America, Europe, and the Middle East. These markets include those in the United States, India, South Africa, and other countries in those regions. 

The company has a strong presence in the anti-infective, gastro-intestinal, central nervous system, and women's health sectors and holds a leadership position in the cardiovascular, anti-diabetic, and respiratory segments. By prescriptions, Lupin ranks as the third-largest pharmaceutical firm in the United States. 

In FY23, the business spent 7.9% of its revenue on research & development. With 15 production facilities, 7 research facilities, and over 20,000 employees worldwide, Lupin has received regular recognition as a "Great Place to Work" in the biotechnology and pharmaceutical industry.

Source: Media reports